Shaiksikkender Abdullah, S (2015) A Comparative Study of Efficacy and Safety of Pitavastatin and Atorvastatin in Dyslipidemic Patients. Masters thesis, K.M. College Of Pharmacy, Madurai.
|
Text
261240058Shaiksikkender Abdullah.pdf Download (1MB) | Preview |
Abstract
AIM OF THE STUDY:The presenst study were To assess the percentage reduction in lipid levels achieved in pitavastatin and atorvastatin. Using optimal guideline based prophylactic treatment of dyslipidemia. To find the co-relation between the pitavastatin and atorvastatin administered and changes of lipid levels To define patient groups who are at high risk for dyslipidemia. To analyse the percentage of adverse effect in pitavastatin and atorvastatin.OBSERVATION AND RESULTS:Clinical characteristics In this study totally 100 patients were examined. 80 of them had CAD. Due to side effects and other reasons 20 patients discontinued from treatment. Only 60 patients of them had regular treatment. The baseline clinical characteristics of patients with Pitavastatin and Atorvastatin are summarized in the table. Out of the 60 patients in the study Diabetes was present in 20 (20%) and Hypertension in 32 (32%) at baseline. These patients were significantly older, had a higher systolic BP and a higher incidence of Hypertension Age Distribution Although the age differed between the Pitavastatin and Atorvastatin group, the incidence of Dyslipidemia in patients older than 50 years were higher when compared with younger patients. Statistical analysis using student unpaired t-test shows that the p-value is 0.3396 and 0.0773 since the p value is greater than 0.05 the incidence of Dyslipidemia in elderly patients is not statistically significant.CONCLUSIONS:Patients treated with Pitavastatin had significantly greater reductions in LDL cholesterol, total cholesterol, triglycerides levels compared with those receiving Atorvastatin. Patients receiving Pitavastatin were more likely to attain lipid goals compared with patients treated with Atorvastatin The recommended starting doses, Pitavastatin (1-2 mg) is more efficacious than Atorvastatin (20-40 mg), in terms of cholesterol, HDL, LDL, and TG better in the lipid profile. The greater efficacy of Pitavastatin at starting dose should help to reduce the need for higher dosage and enable more Patients to achieve recommended treatment goals in clinical practice. Moreover there is, improvements in the whole lipid profile, including rise in HDL-C.
| Item Type: | Thesis (Masters) |
|---|---|
| Uncontrolled Keywords: | Pitavastatin ; Atorvastatin ; Dyslipidemic Patients. |
| Subjects: | PHARMACY > Pharmaceutical Chemistry |
| Depositing User: | Ravindran C |
| Date Deposited: | 18 Dec 2017 07:50 |
| Last Modified: | 18 Dec 2017 07:50 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/4386 |
Actions (login required)
 |
View Item |
